Literature DB >> 2805171

Binding of sulfonamides to erythrocytes and their components.

K Matsumoto, H Miyazaki, T Fujii, M Hashimoto.   

Abstract

Binding of zonisamide, a new antiepileptic sulfonamide derivative, was examined to human erythrocytes, their lysate and their carbonic anhydrase by centrifugation for cells or by ultrafiltration for the others. Scatchard plots revealed that the binding to intact and lysed cells was composed of high- and low-affinity components and that to carbonic anhydrase, of the high-affinity component alone. Parameters for high-affinity binding were similar in all three preparations and those for low-affinity binding were similar in the former two preparations. Dissociation constants for these bindings to erythrocytes were smaller than the dissociation constant for serum albumin. These results may explain the concentration of sulfonamides in red cells, and suggest the participation of cellular protein component(s) in addition to previously known carbonic anhydrase in the binding. Acetazolamide, sulthiame, zonisamide, hydrochlorothiazide and sulfanilamide inhibited carbonic anhydrase in a non-competitive manner to different extents. The Ki values of these sulfonamides were of the order of 0.1--0.2 of their respective Kd values determined by ultrafiltration, suggesting that under the present conditions, physicochemical interactions between sulfonamides and carbonic anhydrase primarily occur at common sites that affect the activity of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2805171     DOI: 10.1248/cpb.37.1913

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  6 in total

Review 1.  Metabolism and excretion of mood stabilizers and new anticonvulsants.

Authors:  T A Ketter; M A Frye; G Corá-Locatelli; T A Kimbrell; R M Post
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 3.  The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.

Authors:  E Perucca; M Bialer
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 4.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

5.  Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers.

Authors:  Margherita Strolin Benedetti; Rhys Whomsley; Jean-Marie Nicolas; Colin Young; Eugène Baltes
Journal:  Eur J Clin Pharmacol       Date:  2003-10-07       Impact factor: 2.953

6.  Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.

Authors:  Kim Dao; Paul Thoueille; Laurent A Decosterd; Thomas Mercier; Monia Guidi; Carine Bardinet; Sébastien Lebon; Eva Choong; Arnaud Castang; Catherine Guittet; Luc-André Granier; Thierry Buclin
Journal:  Pharmacol Res Perspect       Date:  2020-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.